All In Biotech

Drug Trial Radar · NCT05721573

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 272 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

272

Actual

Start

Feb 28, 2023

Primary completion

Nov 6, 2025

Study completion Nov 27, 2025

Sponsor

Lead sponsor
Abcuro, Inc.Industry
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Feb 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

Conditions

  • Inclusion Body Myositis

Interventions

  • ABC008Drug

    Given by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Week 80
  2. Part A: Number of Participants With TEAEs by SeverityTime frame: Up to Week 80
  3. Part A: Number of Participants With TEAEs Related to Study DrugTime frame: Up to Week 80
  4. Part A: Mean Change From Baseline in the Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score at Week 76Time frame: Baseline (Day 1) and at Week 76
  5. Part B: Number of Participants With TEAEsTime frame: Day 1 to Week 80
  6. Part B: Number of Participants With TEAEs by SeverityTime frame: Day 1 to Week 80
  7. Part B: Number of Participants With TEAEs Related to Study DrugTime frame: Day 1 to Week 80
  8. Part B: Mean Change From Baseline in the IBMFRS Total Score at Week 76Time frame: Baseline (Day 1) and Up to Week 76
  9. Part C: Time to PD RecoveryTime frame: Up to Week 24

Locations

45 sites in 7 countries. Site status is shown where the registry gives one.

  • Neuromuscular Research Center

    Phoenix, Arizona

  • University of California Irvine Medical Center (UCIMC) - Amyotrophic Lateral Sclerosis (ALS) and Neuromuscular Center

    Irvine, California

  • Keck Hosptial of USC

    Los Angeles, California

  • UCLA Medical Center

    Los Angeles, California

  • Stanford Neuroscience Medical Center

    Palo Alto, California

  • University of California, San Francisco

    San Francisco, California

  • University of Colorado Hospital Anschutz Outpatient Pavillion

    Aurora, Colorado

  • Yale School of Medicine

    New Haven, Connecticut

  • Mayo Clinic

    Jacksonville, Florida

  • Northwestern Memorial Hospital, Department of Neurology (Clinic)

    Chicago, Illinois

  • University of Kansas Medical

    Kansas City, Kansas

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Neuromuscular Diagnostic Center - Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Womens Hospital

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hospital for Special Surgery

    New York, New York

  • Columbia University Medical Center / The Neurological Institute of New York

    New York, New York

  • Duke Neurological Disorders Clinic -1L

    Durham, North Carolina

  • Wake Forrest School of Medicine

    Winston-Salem, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • UPMC Arthritis and Autoimmunity Center, Falk Clinic

    Pittsburgh, Pennsylvania

  • Austin Neuromuscular Center

    Austin, Texas

  • Texas Neurology

    Dallas, Texas

  • Nerve and Muscle Center of Texas

    Houston, Texas

  • Virginia Commonwealth University

    Henrico, Virginia

  • University of Washington Medical Center - Montlake

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Perron Institute for Neurological and Translational Science

    Nedlands, Western Australia, Australia

  • AZ Sint-Lucas & Volkskliniek

    Ghent, Belgium

  • Heritage Medical Research Clinic - University of Calgary

    Calgary, Alberta, Canada

  • Genge Partners Inc.

    Montreal, Quebec, Canada

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.